Lyell Immunopharma updated its Phase 1 trial of LYL273, a CAR T-cell therapy for relapsed or refractory metastatic colorectal cancer, showing gastrointestinal prophylaxis significantly reduced severe diarrhea and colitis from 55% to 10%. No severe cytokine release syndrome or neurotoxicity was observed under the new safety plan. The trial has been amended to a Phase 1/2 design to allow seamless expansion into a pivotal Phase 2 trial, including new cohorts for second-line treatment and combination with radiotherapy. Additional clinical data and an FDA End-of-Phase 1 meeting are expected in late 2026, advancing LYL273's development with Fast Track designation from the FDA.
SharonAI Holdings Inc. received a buy rating due to its significant $2.2 billion in AI compute contracts and early customer commitments, addressing a key industry bottleneck. Strategic partnerships with NVIDIA and NEXTDC add credibility and reduce de...
Bitcoin and ether spot ETFs attracted a combined $282 million inflow during July 7-11, halting an eight-week streak of outflows that saw $9.46 billion leave these products. This inflow signals a potential stabilization in institutional interest after...
U.S. spot Bitcoin ETFs recorded $90.44 million in net inflows on July 10, reversing two days of outflows and indicating stable institutional demand. BlackRock's iShares Bitcoin Trust led with $86.83 million of the inflows, highlighting its dominance ...
Metaplanet, along with JPYC and Progmat, launched a study on July 10, 2026, to explore bitcoin-backed digital bonds settled via a yen stablecoin in Japan. The Tokyo-listed company holds 43,000 BTC and recently acquired Siiibo Securities to access 250...
Arizona Gold & Silver has secured a Bureau of Land Management permit to expand drilling at its Philadelphia project in Arizona. This allows the company to establish 16 new drill pads, focusing initially on the Red Hills area to explore deeper extensi...
